(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 2 August 2001 (02.08.2001)

PCT

(10) International Publication Number WO 01/55307 A3

(51)		ent Classification ⁷ : C07K 14	/47,	60/227,182 60/226,681	22 August 2000 (22.08.2000) 22 August 2000 (22.08.2000)	US US
	C12N 3/10, 3/10,	13/12, 13/03, 13/04			-	US
		n n n n n n n n n n n n n n n n n n n		60/227,009	23 August 2000 (23.08.2000)	US
(21)	International App	olication Number: PCT/US01/03	1306	60/228,924	30 August 2000 (30.08.2000)	US
				60/229,344	1 September 2000 (01.09.2000)	
(22)	International Fili	ng Date: 17 January 2001 (17.01.2	001)	60/229,343	1 September 2000 (01.09.2000)	US
				60/229,287	1 September 2000 (01.09.2000)	US
(25)	Filing Language:	Eng	glish	60/229,345	1 September 2000 (01.09.2000)	US
				60/229,513	5 September 2000 (05.09.2000)	US
(26)	Publication Lang	uage: En	glish	60/229,509	5 September 2000 (05.09.2000)	US
()			J	60/230,438	6 September 2000 (06.09.2000)	US
(30)	Priority Data:			60/230,437	6 September 2000 (06.09.2000)	US
(50)	60/179,065	31 January 2000 (31.01.2000)	US	60/231,413	8 September 2000 (08.09.2000)	US
	60/180,628	4 February 2000 (04.02.2000)	US	60/232,080	8 September 2000 (08.09.2000)	US
	60/184,664	24 February 2000 (24.02.2000)	US	60/231,414	8 September 2000 (08.09.2000)	US
	60/186,350	24 Tebruary 2000 (24.02.2000) 2 March 2000 (02.03.2000)	US	60/231,244	8 September 2000 (08.09.2000)	US
	60/189,874	16 March 2000 (16.03.2000)	US	60/232,081	8 September 2000 (08.09.2000)	US
	60/190,076	17 March 2000 (17.03.2000)	US	60/231,242	8 September 2000 (08.09.2000)	US
	60/198,123	18 April 2000 (18.04.2000)	US	60/231,243	8 September 2000 (08.09.2000)	US
=	60/205,515	19 May 2000 (19.05.2000)	US	60/231,968	12 September 2000 (12.09.2000)	US
	60/209,467	7 June 2000 (07.06.2000)	US	60/232,401	14 September 2000 (14.09.2000)	US
		28 June 2000 (28.06.2000)	US	60/232,400	14 September 2000 (14.09.2000)	US
	60/214,886	,	US	60/232,397	14 September 2000 (14.09.2000)	US
	60/215,135	30 June 2000 (30.06.2000)		60/233,063	14 September 2000 (14.09.2000)	US
	60/216,647	7 July 2000 (07.07.2000)	US	60/233,064	14 September 2000 (14.09.2000)	US
	60/216,880	7 July 2000 (07.07.2000)	US	60/233,065	14 September 2000 (14.09.2000)	US
	60/217,487	11 July 2000 (11.07.2000)	US	60/232,398	14 September 2000 (14.09.2000)	US
	60/217,496	11 July 2000 (11.07.2000)	US	60/232,399	14 September 2000 (14.09.2000)	US
	60/218,290	14 July 2000 (14.07.2000)	US	60/234,274	21 September 2000 (21.09.2000)	US
	60/220,963	26 July 2000 (26.07.2000)	US	60/234,223	21 September 2000 (21.09.2000)	US
	60/220,964	26 July 2000 (26.07.2000)	US	60/234,997	25 September 2000 (25.09.2000)	US
=	60/225,757	14 August 2000 (14.08.2000)	US	60/234,998	25 September 2000 (25.09.2000)	US
=	60/225,270	14 August 2000 (14.08.2000)	US	60/235,484	26 September 2000 (26.09.2000)	US
	60/225,447	14 August 2000 (14.08.2000)	US	60/235,834	27 September 2000 (27.09.2000)	US
	60/225,267	14 August 2000 (14.08.2000)	US	60/235,836	27 September 2000 (27.09.2000)	US
=	60/225,758	14 August 2000 (14.08.2000)	US	60/236,369	29 September 2000 (29.09.2000)	US
	60/225,268	14 August 2000 (14.08.2000)	US	60/236,327	29 September 2000 (29.09.2000)	US
=	60/224,518	14 August 2000 (14.08.2000)	US	60/236,368	29 September 2000 (29.09.2000)	US
	60/224,519	14 August 2000 (14.08.2000)	US	60/236,367	29 September 2000 (29.09.2000)	US
	60/225,759	14 August 2000 (14.08.2000)	US	60/236,370	29 September 2000 (29.09.2000)	US
	60/225,213	14 August 2000 (14.08.2000)	US	60/237,037	2 October 2000 (02.10.2000)	US
_	60/225,266	14 August 2000 (14.08.2000)	US	60/236,802	2 October 2000 (02.10.2000)	US
	60/225,214	14 August 2000 (14.08.2000)	US	60/237,039	2 October 2000 (02.10.2000)	US
	60/226,279	18 August 2000 (18.08.2000)	US	60/237,038	2 October 2000 (02.10.2000)	US
ח	60/226,868	22 August 2000 (22.08.2000)	US	60/237,040	2 October 2000 (02.10.2000)	US
ť					[Continued on next p	page]

(54) Title: NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

(57) Abstract: The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosis, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

VO 01/5530



60/239,937	13 October 2000 (13.10.2000)	US
60/239,935	13 October 2000 (13.10.2000)	US
60/241,785	20 October 2000 (20.10.2000)	US
60/241.809	20 October 2000 (20.10.2000)	US
60/240,960	20 October 2000 (20.10.2000)	US
60/241,787	20 October 2000 (20.10.2000)	US
60/241.808	20 October 2000 (20.10.2000)	US
60/241,221	20 October 2000 (20.10.2000)	US
60/241,786	20 October 2000 (20.10.2000)	US
60/241,826	20 October 2000 (20.10.2000)	US
60/244,617	1 November 2000 (01.11.2000)	US
60/246,474	8 November 2000 (08.11.2000)	US
60/246,532	8 November 2000 (08.11.2000)	US
60/246,476	8 November 2000 (08.11.2000)	US
60/246,526	8 November 2000 (08.11.2000)	US
60/246,475	8 November 2000 (08.11.2000)	US
60/246,525	8 November 2000 (08.11.2000)	US
60/246,528	8 November 2000 (08.11,2000)	US
60/246,527	8 November 2000 (08.11.2000)	US
60/246,477	8 November 2000 (08.11.2000)	US
60/246,611	8 November 2000 (08.11.2000)	US
60/246,610	8 November 2000 (08.11.2000)	US
60/246,613	8 November 2000 (08.11.2000)	US
60/246,609	8 November 2000 (08.11.2000)	US
60/246,478	8 November 2000 (08.11.2000)	US
60/246,524	8 November 2000 (08.11.2000)	US
60/246,523	8 November 2000 (08.11.2000)	US
60/249,299	17 November 2000 (17.11.2000)	US
60/249,210	17 November 2000 (17.11.2000)	US
60/249,216	17 November 2000 (17.11.2000)	US
60/249,217	17 November 2000 (17.11.2000)	US
60/249,211	17 November 2000 (17.11.2000)	US
60/249,215	17 November 2000 (17.11.2000)	US
60/249,218	17 November 2000 (17.11.2000)	US
60/249,208	17 November 2000 (17.11.2000)	US
60/249,213	17 November 2000 (17.11.2000)	US
60/249,212	17 November 2000 (17.11.2000)	US
60/249,207	17 November 2000 (17.11.2000)	US
60/249,245	17 November 2000 (17.11.2000)	US
60/249,244	17 November 2000 (17.11.2000)	US
60/249,297	17 November 2000 (17.11.2000)	US
60/249,214	17 November 2000 (17.11.2000)	US
60/249,264	17 November 2000 (17.11.2000)	US
60/249,209	17 November 2000 (17.11.2000)	US
60/249,300	17 November 2000 (17.11.2000)	US
60/249,265	17 November 2000 (17.11.2000)	US
60/250,391	1 December 2000 (01.12.2000)	US
60/250,160	1 December 2000 (01.12.2000)	US
60/256,719	5 December 2000 (05.12.2000)	US
60/251,030	5 December 2000 (05.12.2000)	US
60/251,988	5 December 2000 (05.12.2000)	US
60/251,479	6 December 2000 (06.12.2000)	US
60/251,869	8 December 2000 (08.12.2000)	US
60/251,856	8 December 2000 (08.12.2000)	US
60/251,868	8 December 2000 (08.12.2000)	US

60/251,990	8 December 2000 (08.12.2000)	US
60/251,989	8 December 2000 (08.12.2000)	US
60/254,097	11 December 2000 (11.12.2000)	US
60/259,678	5 January 2001 (05.01.2001)	US

(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). BARASH, Steven, C. [US/US]; 111 Watkins Pond Blvd., #301, Rockville, MD 20850 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).
- (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 10 January 2002

(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 36/2001 of 7 September 2001, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/01306

A. CLASSIFICATION OF SUBJECT MATTER IPC(7): C07K 14/47; C12N 5/10, 5/16, 15/12, 15/63, 15 US CL: Please See Extra Sheet. According to International Patent Classification (IPC) or to both						
B. FIELDS SEARCHED						
Minimum documentation searched (classification system follow	ed by classification symbols)					
U.S. : 530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1						
Documentation searched other than minimum documentation to the	e extent that such documents are included i	n the fields searched				
Electronic data base consulted during the international search (r	name of data base and, where practicable,	search terms used)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT		W				
Category* Citation of document, with indication, where a	appropriate, of the relevant passages	Relevant to claim No.				
X WO 92/05256 A1 (GENETICS INSTITUTE) 02 April 1992 (02/0 especially pages 17-21.	ITUTE, INC., THE WISTAR 4/92), see entire document,	1-2, 7-11, 14-16 3-6, 12, 21				
Further documents are listed in the continuation of Box C	See assess for the					
Special categories of cited documents: A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the intendate and not in conflict with the application the principle or theory underlying the intended after the principle of particular relevance, the	ation but cited to understand				
"E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other	considered novel or cannot be considere when the document is taken alone	d to involve an inventive step				
special reason (as specified) O* document referring to an oral disclosure, use, exhibition or other means	"Y" document of particular relevance; the considered to involve an inventive a combined with one or more other such a being obvious to a person skilled in the	step when the document is				
P* document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent f	1				
Date of the actual completion of the international search	Date of mailing of the international search	ch report				
24 APRIL 2001	0 9 JUL 20	01				
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Pacsimile No. (703) 305-3230	Authorized officer PREMA MERTZ TERRY PARAL FGAL Telephone No. (703) 308 6136	SPECIALIST				
orm PCT/ISA/210 (second sheet) (July 1998) *	Telephone No. (703) 208 0106 OGV	CENTER 1600				

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/01306

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
Please See Extra Sheet.
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. X No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12,1 4-16, 21 (SEQ ID NO:11, 24)
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/01306

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-12, 14-16, 21, drawn to a nucleic acid of SEQ ID NO:11 encoding a protein of SEQ ID NO:24, a vector, a host cell, a method of making the protein and the protein of SEQ ID NO:24.

Group II, claim 13, drawn to an antibody that binds the protein of SEQ ID NO:24.

Group III, claim 17, drawn to a method of treating a condition comprising administering the polynucleotide encoding the protein of SEQ ID NO:24.

Group IV, claim 18, drawn to a method of diagnosing a pathological condition using the polynucleotide encoding a protein of SEQ ID NO:24.

Group V, claim 19, drawn to a method of diagnosing a pathological condition by determining the amount of protein of SEQ ID NO:24.

Group VI, claim 20, drawn to a method of identifying a binding partner of the protein of SEQ ID NO:24.

Group VII, claims 22-23, drawn to a method of identifying an activity in a biological assay.

Group VIII, claim 17, drawn to a method for treating a condition comprising administering the polypeptide of SEQ ID

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the

main invention (Group I) comprises the first-recited product, a nucleic acid encoding a protein of SEQ ID NO:24, a vector, a host cell, a method of making the protein of SEQ ID NO:24, and the protein of SEQ ID NO:24. Further

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

the polynucleotides set forth in SEQ ID NO:11-17 encoding the polypeptides set forth in SEQ ID NO:24-30.